NEW YORK, Oct. 6 (GenomeWeb News) - Ingenium Pharmaceuticals said today that it has expanded its drug discovery partnership with Elan to include areas outside pain management.
In March, the companies inked a deal under which Ingenium uses its functional genomics tools to identify and clone for Elan molecular targets involved in the molecular mechanisms involved in the control of pain.
According to Ingenium, it has been producing genetically altered mouse models for Elan's use in pain management drug target validation. With the expansion of the deal, it will produce additional models to be used in other areas of research.
Specific terms of the deal were not disclosed.